REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Rating of “Moderate Buy” from Analysts

REGENXBIO Inc. (NASDAQ:RGNX) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $27.80.

Several equities research analysts have recently commented on RGNX shares. HC Wainwright lowered their price target on shares of REGENXBIO from $34.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of REGENXBIO in a report on Thursday, January 22nd. The Goldman Sachs Group cut their price target on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Stifel Nicolaus raised their price target on REGENXBIO from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Finally, UBS Group reaffirmed an “overweight” rating and set a $18.00 price objective on shares of REGENXBIO in a research note on Tuesday, February 10th.

REGENXBIO Stock Down 4.3%

Shares of RGNX opened at $7.99 on Tuesday. The stock’s fifty day simple moving average is $12.97 and its 200-day simple moving average is $11.42. The firm has a market capitalization of $404.45 million, a PE ratio of -2.30 and a beta of 1.05. REGENXBIO has a 12-month low of $5.03 and a 12-month high of $16.19.

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently bought and sold shares of RGNX. AQR Capital Management LLC raised its stake in REGENXBIO by 2,247.7% during the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after buying an additional 594,161 shares during the period. Jane Street Group LLC increased its holdings in shares of REGENXBIO by 151.1% in the first quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company’s stock worth $2,961,000 after acquiring an additional 249,156 shares in the last quarter. CWM LLC raised its position in shares of REGENXBIO by 75.4% during the second quarter. CWM LLC now owns 46,816 shares of the biotechnology company’s stock worth $384,000 after purchasing an additional 20,120 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of REGENXBIO during the 2nd quarter valued at about $1,453,000. Finally, Savant Capital LLC acquired a new position in shares of REGENXBIO in the 2nd quarter valued at approximately $226,000. Institutional investors own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.